Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

Area of Science:

• Rare genetic disorders
• Lysosomal storage diseases
• Enzyme replacement therapy

Background:

• Fabry disease is a rare, X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency.
• It can lead to severe renal, cardiac, and cerebrovascular complications, potentially causing early death.

Purpose of the Study:

• To evaluate if agalsidase beta can delay a composite clinical outcome in patients with advanced Fabry disease.
• Assessing the impact on renal, cardiovascular, and cerebrovascular events, as well as mortality.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 82 adults with mild to moderate kidney disease across 41 international centers.
• Patients received intravenous agalsidase beta (1 mg/kg) or placebo every two weeks for up to 35 months.
• The primary endpoint was the time to the first clinical event (renal, cardiac, cerebrovascular, or death).

Main Results:

• Agalsidase beta showed a trend towards delaying the primary composite clinical outcome (HR, 0.47; P=0.06) in the intention-to-treat analysis.
• Secondary analyses in protocol-adherent patients indicated a significant delay (HR, 0.39; P=0.034).
• Larger treatment effects were observed in patients with higher baseline estimated glomerular filtration rates (eGFR > 55 mL/min/1.73 m²).

Conclusions:

• Agalsidase beta therapy demonstrated a potential to slow disease progression in advanced Fabry disease.
• The study suggests that initiating therapeutic intervention before irreversible organ damage may yield greater clinical benefits.
• Limitations include a small sample size and a relatively low event rate.